Clinical Research Directory
Browse clinical research sites, groups, and studies.
TLN-372 in Advanced KRAS Mutant Solid Tumors
Sponsor: Treeline Biosciences, Inc.
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Official title: An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-09-29
Completion Date
2032-04-01
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
TLN-372
Specified dose on specified days
TLN-372 in combination with cetuximab
Specified dose on specified days
TLN-372 in combination with pembrolizumab
Specified dose on specified days
Locations (10)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
START Midwest
Grand Rapids, Michigan, United States
Washington University Medical Campus
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
Madrid, Spain